HCC Screening Using DNA Methylation Changes in ctDNA
Study Details
Study Description
Brief Summary
Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship. Follow up of high-risk populations such as chronic hepatitis patients and early diagnosis of transitions from chronic hepatitis to HCC would improve cure rates. In most cases HCC is detected late resulting in increased mortality and morbidity.
The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in hepatocellular carcinomas patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| chronic hepatitis B This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline. |
Diagnostic Test: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
|
| HCC Cases This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma. HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma |
Diagnostic Test: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
|
| Healthy This group will include 50 healthy sex and age matched controls. |
Diagnostic Test: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
|
Outcome Measures
Primary Outcome Measures
- DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC [6 months to 1 year]
We will develop the linear model and a threshold value differentiating breast cancer from control based on the 100 patient training set. The model will be provided to the researchers: Methylation score=CG1*b1+CG2*b2+ CG3*b3 + e CG1 is the methylation value of the first CG b1 is the regression coefficient for the first CG and e equals the intercept. We will develop the regression coefficient and intercept as well as the DNA methylation values for each patient for each CG. We will first compute the polygenic methylation score for each patient. Then based on the computer threshold based on the training cohort will call the samples as liver cancer or not.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed diagnosis of HCC by EASL-EORTC guidelines
-
Confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines.
Exclusion Criteria for HCC:
-
Cirrhosis, any other known inflammatory disease (bacterial or viral infection with the exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid disease) which could alter T cells and monocytes characteristics
-
Other cancers.
Exclusion Criteria for HepB:
- Diagnosis of HCC or any other cancer.
Exclusion Criteria for Healthy Controls:
-
Any known inflammatory or infectious disease including HepB and HepC
-
Chronic diseases,
-
Cancer
-
Medications or drug use
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Infectious Diseases Division | Dhaka | Bangladesh |
Sponsors and Collaborators
- HKGepitherapeutics
- International Centre for Diarrhoeal Disease Research, Bangladesh
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HKG-Bng-HCC-100